Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer
Authors
Keywords
-
Journal
BMC GASTROENTEROLOGY
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-09-04
DOI
10.1186/s12876-023-02930-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification and validation of EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in colon cancer
- (2022) Ning Kang et al. BMC GASTROENTEROLOGY
- Identification and Validation of Immune Cells and Hub Genes in Gastric Cancer Microenvironment
- (2022) Huan Wang et al. DISEASE MARKERS
- AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma
- (2022) Yingqing Liu et al. Scientific Reports
- Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches
- (2022) Sangjoon Choi et al. Biomedicines
- ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer
- (2022) Wenchao Gu et al. Cancer Medicine
- Identification of molecular patterns and prognostic models of epithelial–mesenchymal transition- and immune-combined index in the gastric cancer
- (2022) Xiuyuan Zhang et al. Frontiers in Pharmacology
- Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer
- (2022) Junquan Song et al. Frontiers in Immunology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Integrated Analysis of the Prognosis-Associated RNA-Binding Protein Genes and Candidate Drugs in Renal Papillary Cell Carcinoma
- (2021) Silin Jiang et al. Frontiers in Genetics
- Identification of novel autophagy-related lncRNAs associated with a poor prognosis of colon adenocarcinoma through bioinformatics analysis
- (2021) Dejun Wu et al. Scientific Reports
- Type I collagen promotes tumor progression of integrin β1 positive gastric cancer through a BCL9L/β-catenin signaling pathway
- (2021) Yalei Lv et al. Aging-US
- Integrin β1 orchestrates the abnormal cell-matrix attachment and invasive behaviour of E-cadherin dysfunctional cells
- (2021) Joana Figueiredo et al. Gastric Cancer
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers
- (2021) Tiantian Wu et al. Frontiers in Immunology
- Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
- (2021) Yuang Wei et al. Frontiers in Genetics
- Advances in clinical immunotherapy for gastric cancer
- (2021) Kexin Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- ITGB1-DT/ARNTL2 axis may be a novel biomarker in lung adenocarcinoma: a bioinformatics analysis and experimental validation
- (2021) Bai-Quan Qiu et al. Cancer Cell International
- Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
- (2021) H. Kim et al. Clinical & Translational Oncology
- SNAI1 is a prognostic biomarker and correlated with immune infiltrates in gastrointestinal cancers
- (2020) Jiaying Fang et al. Aging-US
- Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer
- (2020) Hongkai Zhuang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1
- (2020) Xiao Wang et al. Bioengineered
- First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
- (2020) Hyun Cheol Chung et al. Future Oncology
- Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
- (2019) Yuanyuan Jiang et al. CANCER LETTERS
- Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy
- (2019) Jeffrey C. Thompson et al. LUNG CANCER
- Contextual determinants of TGFβ action in development, immunity and cancer
- (2018) Charles J. David et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Prognostic role of tumor-infiltrating lymphocytes in gastric cancer
- (2018) Jung Soo Lee et al. MEDICINE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- TGFΒ-induced transcription in cancer
- (2017) Gaia Cantelli et al. SEMINARS IN CANCER BIOLOGY
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Interaction between Wnt/β-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (Review)
- (2016) CUNEN WU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGF-β1-Induced Epithelial–Mesenchymal Transition Promotes Monocyte/Macrophage Properties in Breast Cancer Cells
- (2015) Joel Johansson et al. Frontiers in Oncology
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Glycogen synthase kinase-3 beta regulates Snail and β-catenin expression during Fas-induced epithelial–mesenchymal transition in gastrointestinal cancer
- (2013) Haoxuan Zheng et al. EUROPEAN JOURNAL OF CANCER
- Fas signaling promotes motility and metastasis through epithelial–mesenchymal transition in gastrointestinal cancer
- (2012) H X Zheng et al. ONCOGENE
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now